Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Published in: Current Hematologic Malignancy Reports 6/2022

30-08-2022 | Multiple Myeloma | Health Economics (N Khera, Section Editor)

Value in Myeloma Care: Myth or Reality

Authors: Evguenia Ouchveridze, Katherine Berger, Ghulam Rehman Mohyuddin

Published in: Current Hematologic Malignancy Reports | Issue 6/2022

Login to get access

Abstract

Purpose of Review

Despite tremendous advances in multiple myeloma (MM) care, the disease maintains considerable morbidity and requires long-term treatment associated with significant financial toxicity to patients and high costs to society. In this review, we explore why — despite treatment advances — value in MM treatment is largely a myth, then explain some ways the myth might become a reality.

Recent Findings

We discuss how value-based care in MM should include patient-centered outcomes such as financial toxicity and quality of life, which are heavily impacted by cost of drugs and the indefinite duration of therapy that is standard in MM treatment. We propose multiple paths to work toward reducing cost and augmenting value of care for patients with MM, including improving access to generic drugs, increasing federal funding for clinical trials, designing more patient-centric clinical trials, and exploring the utilization of minimal residual disease (MRD)-driven treatment de-escalation, among others.

Summary

We remain optimistic that despite the challenges, we can work toward making progress in the realm of value-based care for patients with MM and make it a reality.
Appendix
Available only for authorised users
Literature
1.
Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, Heffner LT, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38(17):1928–37.CrossRefPubMedPubMedCentral
2.
3.
Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, et al. Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J. 2022;12(4):74.CrossRefPubMedPubMedCentral
4.
Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I, et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica. 2018;103(9):e412–e5.CrossRefPubMedPubMedCentral
5.
Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111(5):2521–6.CrossRefPubMed
6.
Bhattacharya K, Bentley JP, Ramachandran S, Chang Y, Banahan BF 3rd, Shah R, et al. Phase-specific and lifetime costs of multiple myeloma among older adults in the US. JAMA Netw Open. 2021;4(7):e2116357.CrossRefPubMedPubMedCentral
7.
Vincent RS. The high cost of prescription drugs: causes and solutions. Blood Cancer J. 2020;10(6):71.CrossRef
8.
9.
10.
11.
12.
Dusetzina SB. Your money or your life — the high cost of cancer drugs under Medicare Part D. New England JMed 2022.
13.
Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844–53.CrossRefPubMedPubMedCentral
14.
Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177(11):1569–75.CrossRefPubMedPubMedCentral
15.
16.
17.
Gyawali B, Hey SP, Kesselheim AS. Evaluating the evidence behind the surrogate measures included in the FDA’s table of surrogate endpoints as supporting approval of cancer drugs. E Clin Med. 2020;21:100332.
18.
Mohyuddin GR, Koehn K, Abdallah AO, Sborov W, Rajkumar D, Kumar SV, Mc Clune B, et al. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: a systematic review. Am J Hematol. 2021;96(6):690–7.CrossRefPubMed
19.
Chakraborty R, Cannella L, Cottone F, Efficace F. Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review. Lancet Haematol. 2020;7(12):e892–901.CrossRefPubMed
20.
Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, et al. Minimal residual disease in myeloma: application for clinical care and new drug registration. Clin Cancer Res. 2021.
21.
Delforge M, Shah N, Miguel JSF, Braverman J, Dhanda DS, Shi L, et al. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022;6(4):1309–18.CrossRefPubMedPubMedCentral
22.
Mohyuddin GR, Koehn K, Abdallah AO, Goodman AM, Prasad V. Reporting of postprotocol therapies and attrition in multiple myeloma randomized clinical trials: a systematic review. JAMA Netw Open. 2021;4(4):e218084.CrossRefPubMedPubMedCentral
23.
Mohyuddin GR, Mian H. Daratumumab in newly diagnosed MM - incorporating lessons learnt from CASSIOPEIA, MAIA and beyond. Nat Rev Clin Oncol. 2022;19(1):3–4.CrossRefPubMed
24.
25.
Oerlemans S, Bennink MC, Levin MD, Broijl A, Van der Klift M, Van Deursen J, et al. Development of a patient centered outcome set for patients with multiple myeloma to be used in clinical practice. Hemasphere. 2020;4(3):e366.CrossRefPubMedPubMedCentral
26.
Witte J, Mehlis K, Surmann B, Lingnau R, Damm O, Greiner W, et al. Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications. Ann Oncol. 2019;30(7):1061–70.CrossRefPubMedPubMedCentral
27.
Huntington SF, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol. 2015;2(10):e408–16.CrossRefPubMed
28.
Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, et al. Characteristics of clinical trials for haematological malignancies from 2015 to 2020: a systematic review. Eur J Cancer. 2022;167:152–60.CrossRefPubMed
29.
Moreau P, Rajkumar SV. Multiple myeloma--translation of trial results into reality. Lancet. 2016;388(10040):111–3.CrossRefPubMed
30.
Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, et al. Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematol. 2021;8(4):e299–304.CrossRefPubMed
31.
Unprecedented outcomes of Isatuximab [press release].
32.
Antonanzas F, Terkola R, Postma M. The value of medicines: a crucial but vague concept. Pharmacoeconomics. 2016;34(12):1227–39.CrossRefPubMed
33.
Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015;90(8):996–1000.CrossRefPubMed
34.
How a drugmaker gamed the system to keep generic competition away.
35.
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–15.CrossRefPubMed
36.
Kapoor P, Rajkumar SV. MAIA under the microscope - bringing trial design into focus. Nat Rev Clin Oncol. 2019;16(6):339–40.CrossRefPubMed
37.
Moreau P, Sonneveld P, Investigators ftCS. Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. J Clin Oncol. 2021;39(15_suppl):8004.CrossRef
38.
Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988–99.CrossRefPubMedPubMedCentral
39.
Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021;35(1):18–30.CrossRefPubMed
40.
Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol 2021 JCO2101935.
41.
Ray A, Ravillah D, Das DS, Song Y, Nordstrom E, Gullbo J, et al. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol. 2016;174(3):397–409.CrossRefPubMedPubMedCentral
42.
Olivier T, Prasad V. The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA. Transl Oncol. 2022;18:101374.CrossRefPubMedPubMedCentral
43.
Ehrhardt S, Appel LJ, Meinert CL. Trends in National Institutes of Health funding for clinical trials registered in ClinicalTrials.gov. JAMA. 2015;314(23):2566–7.CrossRefPubMedPubMedCentral
44.
Abola MV, Prasad V. Characteristics and conflicts of public speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration. JAMA Intern Med. 2016;176(3):389–91.CrossRefPubMed
45.
Wayant C, Turner E, Meyer C, Sinnett P, Vassar M. Financial conflicts of interest among oncologist authors of reports of clinical drug trials. JAMA Oncol. 2018;4(10):1426–8.CrossRefPubMedPubMedCentral
46.
47.
Fischer KA, Walling A, Wenger N, Glaspy J. Cost health literacy as a physician skill-set: the relationship between oncologist reported knowledge and engagement with patients on financial toxicity. Support Care Cancer. 2020;28(12):5709–15.CrossRefPubMed
48.
Tao DL, Boothby A, McLouth J, Prasad V. Financial conflicts of interest among hematologist-oncologists on Twitter. JAMA Intern Med. 2017;177(3):425–7.CrossRefPubMed
Metadata
Title
Value in Myeloma Care: Myth or Reality
Authors
Evguenia Ouchveridze
Katherine Berger
Ghulam Rehman Mohyuddin
Publication date
30-08-2022
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 6/2022
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-022-00669-1

Other articles of this Issue 6/2022

Current Hematologic Malignancy Reports 6/2022 Go to the issue

T-Cell and Other Lymphoproliferative Malignancies (R Mesa, Section Editor)

Circulating Tumor DNA in Lymphoma

Multiple Myeloma (Prashant Kapoor, Section Editor)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma

Health Economics (N Khera, Section Editor)

Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation

Chronic Myeloid Leukemias (V Oehler, Section Editor)

Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies

Chronic Myeloid Leukemias (V Oehler, Section Editor)

Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication

T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

Bispecific Antibodies for the Treatment of Multiple Myeloma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits